CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancersLeia M. Smith, P. J. Carter, Albina Nesterova et al.|British Journal of Cancer|2008Cited by 289
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trialCharu Aggarwal, Nehal J. Lakhani, Dan P. Zandberg et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 140
Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3John D. Powderly, Bartosz Chmielowski, Gregory M. Coté et al.|Journal for ImmunoTherapy of Cancer|2015Cited by 101
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of CancerLaird Bloom, Wei Cao, Bilian Li et al.|Antibodies|2016Cited by 94
An evaluation of 10 percent and 20 percent benzocaine gels in patients with acute toothachesElliot V. Hersh, Sharon M. Gordon, Sebastian G. Ciancio et al.|The Journal of the American Dental Association|2013Cited by 25